Am J Transplant, Volume 18, Suppl 3 Archives - Page 145 of 211 - ATC Abstracts

2018 American Transplant Congress
Disparity in Access to Kidney Allograft Offers among HIV+ Transplant Candidates
J. Cohen,¹ J. Locke,² B. Shelton,² R. Reed,² P. MacLennan,² D. Sawinski.¹
¹Renal Division, University of Pennsylvania, Philadelphia, PA; ²Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL.
Background: Despite having a demonstrated survival benefit with kidney transplantation, patients with chronic viral infections, such as HCV or HIV, face many barriers to transplantation,…
2018 American Transplant Congress
Disparate Candidate Selection Practices and Substantial Use of Low KDPI Kidneys in Combined Heart-Kidney and Liver-Kidney Transplantation, 2012-2016
R. Steiner,¹ J. Halldorson.²
¹Transplant Nephrology, University of California at San Diego School of Medicine, San Diego, CA; ²Transplant Surgery, Sharp Memorial Hospital/Balboa Nephrology, San Diego, CA.
Transplant professionals have struggled to formulate defensible standards for combined heart-kidney and liver-kidney transplantation (HKTs and LKTs). In these recipients, recovery of native renal function…
2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
C-.H. Cheng,^1,2 C-.F. Lee,^1,2 G. Furtmüller,³ B. Oh,³ C. Patel,¹ Y-.C. Lo,¹ M. Fryer,³ G. Brandacher,³ J. Powell.¹
¹Sidney-Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, New Taipei City, Taiwan; ³Vascularized Composite Allotransplantation Laboratory, Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…
2018 American Transplant Congress
B Cell Immune Repertoire Sequencing Identifies Pre-Transplant Rejection Risk
S. Pineda,^1,2 T. Sigdel,¹ J. Liberto,¹ K. Roskin,³ S. Robin,³ M. Sirota,² M. Sarwal.¹
¹Surgery, UCSF, SF; ²ICHS, UCSF, SF; ³Pathology, Stanford, Stanford.
Background: The diversity of the B cell immune repertoire may drive humoral injury and rejection in organ transplantation (tx).Methods: We utilized advances in next-generation sequencing…
2018 American Transplant Congress
Recipient HO-1 Deficiency Decreases Post-Transplant Graft HO-1 Expression and Exacerbates Liver Transplant Damage
S. Kageyama,¹ K. Nakamura,¹ T. Ito,¹ A. Aziz,¹ B. Ke,¹ R. Sossa,² E. Reed,² F. Kaldas,¹ R. Busuttil,¹ J. Kupiec-Weglinski.¹
¹Surgery, Liver Transplantation, UCLA, Los Angeles, CA; ²Pathology, UCLA, Los Angeles, CA.
Many preclinical studies on protective functions of heme oxygenase-1 (HO-1; hsp32) in orthotopic liver transplantation (OLT) have encouraged application of HO-1 inducing regimens in clinical…
2018 American Transplant Congress
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
N. Bath, S. Parajuli, G. Leverson, M. Jorgenson, J. Fose, T. Ellis, D. Kaufman, A. Djamali, R. Redfield.
Surgery, University of Wisconsin, Madison, WI.
Introduction: Basiliximab, alemtuzumab, and thymoglobulin are the most commonly used induction agents in the US. While many centers use depleting antibody induction therapy in patients…
2018 American Transplant Congress
Modifiable Causes of Racial Disparities in Living Donor Kidney Transplant
J. Beaumont,¹ J. Peipert,^1,2 C. Anderson,² A. Paiva,³ M. Robbins,³ A. Waterman.^1,2
¹Terasaki Research Institute, Los Angeles, CA; ²Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA; ³Department of Psychology, University of Rhode Island, Kingston, RI.
Racial disparities between White and non-White patients in receiving living donor kidney transplants (LDKT) are large and widespread. Yet, the causes of this disparity are…
2018 American Transplant Congress
Outcomes of Pregnancies in Female Liver Transplant Recipients
L. Coscia,¹ D. Armenti,¹ P. Patel,² S. Constantinescu,^1,3 M. Moritz.^1,2,4
¹Transplant Pregnancy Registry International, Gift of Life Institute, Philadelphia, PA; ²Surgery, Lehigh Valley Health Network, Allentown, PA; ³Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA; ⁴Surgery, Morsani College of Medicine, Tampa, FL.
The purpose of this study is to describe 544 pregnancies in 278 liver transplant recipients reporting to the Transplant Pregnancy Registry International (TPR) from 1991…
2018 American Transplant Congress
Enrichment of Endogenous Donor-Reactive Tregs in the Spleen and Graft during Transplantation Tolerance is the Result of Treg Proliferation and Conversion from Tconv
J. Young, D. Yin, M-.L. Alegre, A. Chong.
Surgery and Medicine, University of Chicago, Chicago, IL.
Foxp3+ regulatory T cells (Tregs) are critical mediators of immune tolerance and are absolutely required for allograft tolerance in animal models. In addition, clinical trials…
2018 American Transplant Congress
Cancer Incidence after Kidney Transplantation in Saudi Arabia, Comparing Different Induction Agents
H. AlEid, S. Raza, T. Ali, I. Alahmadi, S. Aleid, D. Broering.
Kidney and Pancreas Transplantation, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
Cancer incidence varies among different induction agents and different population. We aim to compare the incidence of cancer post kidney transplantation among different induction agents…